Skip to main content
. 2024 Jan 10;14:1326078. doi: 10.3389/fimmu.2023.1326078

Figure 1.

Figure 1

Flowchart describing the responses of the reference centers contacted for this study. The contacted referral centers were asked to complete an online survey on patients undergoing immune checkpoint inhibitor (ICI) treatment for malignancies with concomitant autoimmune or cholestatic liver disease (AILD).